Author: Multibagger News

Investment Expert Reveals Shocking Impact of Gaza War on Palestinian Families Ahmed Al-Shanbari and his sons brave danger to forage for food amidst the rubble of Gaza, highlighting the hunger crisis faced by many Palestinians. With limited resources, families like the Al-Shanbaris resort to eating mulberry leaves, a desperate measure to survive in the war-torn region. The ongoing conflict, which began with an attack by Hamas militants on Israel, has resulted in devastating consequences for Gaza’s population. Health authorities report thousands of deaths and widespread famine, with children in northern areas being the most vulnerable. Despite efforts by Israel to…

Discover the Secret Behind Bitcoin’s 400% Surge: A History Lesson for Investors As the world’s leading investment manager and financial market journalist, I have uncovered a fascinating trend in Bitcoin’s price movements that could lead to massive profits for savvy investors. According to a comprehensive analysis of Bitcoin’s past quarterly price movements since 2010, it is clear that the cryptocurrency tends to experience significant price fluctuations after periods of consolidation. For example, in 2013, Bitcoin’s value skyrocketed from $16 to $739 after a period of relative stability. A similar pattern occurred in 2015 and 2017 when Bitcoin consolidated around $230…

Breaking News: Citi (NYSE:C) Fined $136 Million by Federal Regulators for Regulatory Non-Compliance In a recent setback, Citi (NYSE:C) faced fines totaling $136 million from the Federal Reserve and the OCC for failing to comply with a 2020 enforcement action. The regulators pointed out Citi’s lack of progress in improving data quality management and risk controls. Despite the fines, Piper Sandler maintained an Overweight rating and a $70.00 price target on Citi stock. The firm believes that while there may be short-term weakness in the stock, knowledgeable investors will see this as part of a longer remediation journey. Piper Sandler…

UBS Maintains EUR/USD Target at 1.0500 After French Elections | No Immediate Conflict with EU UBS has reaffirmed its long-term target for the EUR/USD exchange rate at 1.0500 following the recent French parliamentary elections. The bank pointed out the underperformance of the far-right National Rally (RN) and the strong showing of President Emmanuel Macron’s centrist party. Despite the uncertainty surrounding the formation of France’s new government, UBS highlighted that a potential conflict between France and the European Union seems to be unlikely at the moment. This outcome has reduced the chance of near-term volatility for the euro, which some FX…

The option market is currently signaling a relatively low probability of a significant downturn for the S&P 500 over the next quarter, according to Piper Sandler. According to the investment bank, there is a 6% chance of the index falling by 10% within the next three months. However, they suggest that this figure could be even lower at around 5%. Piper Sandler’s analysis of the risk-neutral distribution indicates that the market may be overly optimistic about upside potential. They believe the market is assigning an excessive probability of a 10% increase in the S&P 500. Despite the low probability of…

Methode Electronics Sees 15% Stock Surge Despite Q4 Net Loss: What Investors Need to Know CHICAGO – Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interfaces, LED lighting, and power distribution, has unveiled its financial results for the fourth quarter ending April 27, 2024. Following the announcement, Methode Electronics’ shares surged by 15%. Key Financial Highlights Net Loss: Methode reported a net loss of $57.3 million, translating to $1.63 per diluted share. Adjusted Net Loss: Adjusted figures showed a net loss of $7.9 million or $0.23 per diluted share. Revenue: The company recorded revenue…

By Indradip Ghosh In a recent poll conducted by Multibagger, a strong majority of economists predict that the European Central Bank (ECB) will cut its deposit rate twice more this year, with potential cuts in September and December. The balance of risks is seen leaning towards just one additional cut by the end of the year. Despite indications from several Governing Council members, including ECB President Christine Lagarde, that there is no rush to lower borrowing costs further due to high services inflation, record-low unemployment, and elevated wage growth, economists remain confident in their predictions. All 85 economists surveyed expect…

Iran’s Indirect Nuclear Talks with US Still Ongoing via Oman, Says Acting Foreign Minister – What Does This Mean for Global Politics and Your Investments? In a recent statement, Iran’s acting foreign minister, Ali Bagheri Kani, revealed that the country is still engaged in indirect nuclear talks with the United States through Oman. Despite initial hesitance from the US, efforts are being made to set the stage for negotiations with the new Iranian government set to take office soon. The newly elected president, Masoud Pezeshkian, has expressed a desire for a more pragmatic foreign policy and aims to ease tensions…

Goldman Sachs Revises Estimate for Net Inflows into Digital Assets – SEO Optimized Title Goldman Sachs recently updated its estimate for net inflows into digital assets year-to-date (YTD), lowering the figure from $12 billion to $8 billion. This adjustment comes after a thorough reassessment of various contributing factors in the market over the past month. Initially, the $12 billion estimate in mid-June was based on a combination of inflows into cryptocurrency funds, CME futures flow, fundraising by crypto venture capital funds, and adjustments for the shift to new spot ETFs from digital wallets. The revised $8 billion figure now includes…

On Thursday, Ideaya Biosciences (NASDAQ:IDYA) saw its price target increased by Mizuho to $55.00, up from $50.00 previously. This comes after the firm maintained an Outperform rating on the stock following the announcement of promising interim Phase 2 data earlier this week. Ideaya Biosciences released updated interim results from its Phase 2 study of IDE397, the company’s second primary asset. IDE397 is currently being evaluated as a monotherapy for the treatment of MTAP-deleted non-small cell lung cancer (NSCLC) and urothelial cancer (UC). The data showed that IDE397 has demonstrated durable efficacy and has a favorable safety and tolerability profile. As…